|Vaccination Liberation - Information|
Ingredients of Vaccines
Artificially Sweetened Times
Books Videos Tapes
100+ Anti-Vax links
CMV Vaccine IndexPROVACCINE NEWS BACKGROUND INFORMATION:
A vaccine in development
CMV = Cytomegalovirus
ReutersFeb2007 | AlphaVaxNews | NIH/CMV_vaccine
S U M M A R YWhat can we learn from the Pro-Vaccine "News" articles below?
What might be a more realistic approach to this birth defect condition?
http://www.alphavax.com/products/cmv.aspx (Vaccine site advertisement)
"Congenital CMV infection is the leading infectious cause of birth defects in the U.S. and, of the 40,000 infections annually, 7,500-10,000 result in serious sequela for the affected infant including mental retardation and deafness."
Read rest of article, lower on this page.
By blaming birth defects on the Virus, rather than placing blame on the unhealthy internal body environment in which the virus grows, then the focus of prevention becomes a vaccine rather than focusing on the improper diet, toxic environment and lifestyle elements that create the unhealthy internal body environment that is the real problem to be corrected.
We at VacLib promote a vaccine-free lifestyle for the prevention of disease.
Various News articles
Pro-Vaccine NewsSource: Reuters.com
Vaccine might protect against birth-defect virus
Thu Feb 22, 2007 12:35 AM IST140
By Will Dunham
WASHINGTON (Reuters) - An experimental vaccine for a common virus that can cause mental retardation and deafness in some newborns yielded encouraging results in guinea pigs and could lead to a human vaccine, scientists said on Wednesday.
Cytomegalovirus, or CMV, is transmitted to a fetus through the mother's placenta. Women can carry the virus without being aware. Congenital CMV is the second-most common cause of mental retardation in infants, behind only Down syndrome, and also can cause deafness.
The vaccine was given to female guinea pigs before they got pregnant. Vaccinated animals had fewer dead offspring and were less likely to transmit the CMV infection to their babies than unvaccinated guinea pigs, the researchers found.
The animals that got the vaccine gave birth to 28 live babies and four dead ones, a death rate of 13 percent. Those that did not get the vaccine had nine live babies and 12 dead ones, a death rate of 57 percent.
Dr. Mark Schleiss of the University of Minnesota School of Medicine, who led the research, said the study marks a key step toward developing a human vaccine.
"It demonstrates for the first time in a relevant animal model of congenital CMV infection that a vaccine strategy that's being considered for human clinical trials is successful in ameliorating disease in newborns," Schleiss said in a telephone interview.
The so-called vector vaccine, developed along with North Carolina-based AlphaVax Inc., uses an altered virus to deliver one gene from the viral DNA to the recipient's cells.
The study, funded in part by the U.S. National Institutes of Health, appears in the Journal of Infectious Diseases.
"An effective CMV vaccine for women of childbearing age could greatly reduce the disability caused by the virus," Dr. Duane Alexander, director of the NIH's National Institute of Child Health and Human Development, said in a statement.
'PUBLIC HEALTH CRISIS'
"Congenital cytomegalovirus infection is a major public health crisis in the United States today, and the average person on the street doesn't know anything about it," Schleiss said.
"I have these moms come into my practice," Schleiss said, "and invariably what they say to me is, 'I've never heard of this before it happened to me and my baby.'"
About 10 to 15 percent of newborns with congenital CMV end up with a long-term disability like mental retardation, cerebral palsy and deafness. CMV also can damage the placenta, leading to miscarriage.
About 1 percent of U.S. babies are born with the virus, amounting to 40,000 per year, researchers said. Medical experts advising U.S. policymakers have deemed development of a vaccine to prevent cytomegalovirus during pregnancy a high priority.
Cytomegalovirus is found widely around the world and is a type of herpes virus. According to the NIH, CMV infects between 50 to 80 percent of all U.S. adults by age 40. There is no cure for it, although commonly it causes few if any symptoms.
It can cause blindness in AIDS patients.
It is transmitted through close personal contact like kissing or sex or sharing eating utensils, and through blood transfusions and nasal secretions.
AlphaVax said it was seeking U.S. Food and Drug Administration approval for the vaccine.
© Reuters 2007. All Rights Reserved.
Congenital CMV infection is the leading infectious cause of birth defects in the U.S. and, of the 40,000 infections annually, 7,500-10,000 result in serious sequela for the affected infant including mental retardation and deafness. The significance of CMV-related illness was highlighted in a 1999 report written by the Institute of Medicine (IOM) and the National Academy of Sciences; that report estimated the cost of treating CMV-related symptoms in the U.S. at more than $4 billion per year. Based on these findings, the IOM categorized a CMV prophylactic vaccine as the highest priority vaccine target on the basis of cost-effectiveness.
In addition to a universal prophylactic vaccine for CMV, there is a significant need for immunotherapeutic intervention against CMV infection during organ or stem cell transplantation, when patients' immune systems must be suppressed to prevent tissue rejection. This target use should allow rapid development of an CMV alphavaccine. We have demonstrated impressive protection in a neonatal guinea pig CMV model using the alphavaccine system and are advancing a candidate vaccine product towards clinical trials in the transplant population.
Pro-Vaccine NewsPediatr Infect Dis J. 1998 Mar;17(3):200-6.
Safety and immunogenicity of the Towne strain cytomegalovirus vaccine.
Adler SP, Hempfling SH, Starr SE, Plotkin SA, Riddell S.
Department of Pediatrics, Medical College of Virginia/Virginia Commonwealth University, Richmond 23298-0163, USA.
Women with naturally acquired serum antibodies to cytomegalovirus (CMV) are usually protected against both frequent secondary infection and giving birth to infants severely affected by intrauterine CMV infection.
To determine the feasibility of using a live attenuated strain of CMV (Towne) to achieve immunity similar to that provided by wild-type infection, we evaluated a new lot of the Towne strain of CMV in 3 open label trials involving 68 men, 63 women of childbearing age and 13 children, respectively.
Mild local reactions occurred among approximately one-third of subjects. There were no systemic reactions. All 45 subjects tested developed lymphoproliferative responses to CMV. CD8+ class I-restricted cytotoxic T cell responses specific for CMV antigens were detected in three of four subjects and persisted for 6 months. Neutralizing titers were maximal at 2 to 4 months postimmunization, were dose-dependent and were comparable to those induced by natural infection.
These results support further evaluation of the Towne strain of CMV in women at risk for acquiring CMV infection during pregnancy or among children transmitting CMV to pregnant women.